"The rapid industry acceptance and usage by key opinion leaders, scientists, and surgeons shows that Establishment Labs has figured out how to make a meaningful difference in this industry."
New York, NY (PRWEB) July 20, 2016
Establishment Labs, a global medical device company focused on breast implant technologies with a strong emphasis on product development and innovation, announced that existing investors exercised their option to invest an additional $6.84 Million, completing a $28 Million financing. Investors in the financing include Crown Predator Holdings (CPH), JW Funds, and Perceptive Advisors.
"This additional investment allows us to continue our rapid pace of innovation and commercialization,” said Juan José Chacón Quirós, CEO of Establishment Labs, “as well as complete our new GMP compliant, state of the art facility. This facility quadruples our production capacity, and readies us for regulatory clearance in the United States."
“Less than a year after our original investment, the exercise of our investor option shows our confidence in the management team and the business,” said Nick Lewin, Partner at CPH. “There is a real opportunity to be the market leader, not only in patient satisfaction and safety, but also in sales volume, and transform the market in the process.”
According to Jason Wild, Founder and Chief Investment Officer of JW Asset Management, LLC, "Establishment Labs is quickly becoming the premier company in Breast Aesthetics, as they continue to innovate with the best minds in biomedical engineering and Plastic Surgery. The rapid industry acceptance and usage by key opinion leaders, scientists, and surgeons shows that Establishment Labs has figured out how to make a meaningful difference in this industry.”
Joseph Edelman, Chief Executive Officer and Portfolio Manager of Perceptive Advisors added, “This investment is based not only on what Establishment Labs has accomplished but what we believe they are going to accomplish in the future. Our diligence in the space suggests that Motiva-branded implants are a transformational product in the industry, and that Establishment Labs should become the outright market leader.
About Establishment Labs:
Establishment Labs is a global, privately held, breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants (http://www.motivaimplants.com). Utilizing only the highest quality of medical grade silicones, CE-marked Motiva Implants® are rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.
Crown Predator Holdings (CPH) invests in early and growth stage companies with an interest in special situations that do not easily fit into traditional investment categories. CPH leads and co-invests in transactions across all industries, capital structures, and styles. Through an extensive and global network of relationships and support, CPH seeks to add value as partners, not just as investors. Founded in 2006 and based in New York City, CPH is a family office led investment firm.
About JW Asset Management, LLC:
JW Asset Management is a New York based fund manager for five investment partnerships. Jason Wild, a registered pharmacist, is the firm's founder and chief investment officer. JW Asset Management has a strong history of finding opportunities within the specialty pharmaceutical sector. The firm is active in both the public and private equity markets.
About Perceptive Advisors:
Founded in 1999, Perceptive Advisors is focused on supporting the progress of the life sciences industry by identifying opportunities and directing financial resources to the most promising technologies in healthcare. Our dedicated team of industry experts uses a unique balance of scientific, technical and investment expertise to identify opportunities. Perceptive seeks to evaluate opportunities without biases by analyzing and weighing critical data and catalysts assessing the balance between market perception and reality. Perceptive manages approximately $2 billion across our strategies and has a long and successful track record.